Covington Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Covington Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$48K	Hold	743	–	–	﹤0.01%	575
2022 Q2	$53K	Hold	743	–	–	﹤0.01%	555
2022 Q1	$73K	Hold	743	–	–	﹤0.01%	524
2021 Q4	$63K	Hold	743	–	–	﹤0.01%	514
2021 Q3	$59K	Hold	743	–	–	﹤0.01%	528
2021 Q2	$72K	Hold	743	–	–	﹤0.01%	489
2021 Q1	$87K	Hold	743	–	–	﹤0.01%	418
2020 Q4	$83K	Hold	743	–	–	﹤0.01%	414
2020 Q3	$88K	Hold	743	–	–	﹤0.01%	393
2020 Q2	$84K	Hold	743	–	–	﹤0.01%	385
2020 Q1	$50K	Hold	743	–	–	﹤0.01%	420
2019 Q4	$68K	Hold	743	–	–	﹤0.01%	423
2019 Q3	$64K	Hold	743	–	–	﹤0.01%	409
2019 Q2	$78K	Hold	743	–	–	﹤0.01%	378
2019 Q1	$93K	Hold	743	–	–	0.01%	339
2018 Q4	$84K	Sell	743 -182	-20%	-$28.2K	0.01%	349
2018 Q3	$198K	Buy	925 +300	+48%	+$75.3K	0.01%	273
2018 Q2	$175K	Buy	+625	New	+$110K	0.01%	288
2018 Q1	–	Sell	-2,000	Closed	-$184K	–	755
2017 Q4	$184K	Buy	+2,000	New	+$114K	0.01%	297

Other funds holding MDGL

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Covington Capital Management's MDGL Position: Q3 2022 in Review

Covington Capital Management held its Madrigal Pharmaceuticals (MDGL) position steady in Q3 2022 at 743 shares worth $48K. The position accounts for ﹤0.01% of the portfolio, ranked #575.

Covington Capital Management first reported a position in MDGL in Q4 2017 and has held it in 19 quarters since. The position peaked at $198K in Q3 2018. 135 funds tracked by Wall St. Rank hold MDGL as of Q3 2022.

Covington Capital Management held 743 shares of Madrigal Pharmaceuticals worth $48K as of Q3 2022.
Covington Capital Management left its Madrigal Pharmaceuticals share count unchanged in Q3 2022.
Madrigal Pharmaceuticals made up ﹤0.01% of Covington Capital Management's portfolio in Q3 2022, its #575 holding.
Covington Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2017 and has held it in 19 quarters since.
Covington Capital Management's Madrigal Pharmaceuticals position peaked at $198K in Q3 2018.
135 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2022.

Based on Covington Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.